Pharmaceuticals News and Research

RSS

Three new retail stores of China Yongxin Pharmaceuticals opened in 2009

China Yongxin Pharmaceuticals, Inc. ("China Yongxin Pharmaceuticals" or the "Company"), is a leading manufacturer, distributor and retailer of Chinese traditional medicines, pharmaceutical products, natural health products, health food, cosmetics, and medical equipment in Northeastern China. The Company today announced that it had opened three new stores in 2009.

8 Jan 2010

ESF-UB Conference to concentrate on potentially clinically relevant polymorphisms

Pharmacogenetics started in the fifties with the discovery of primaquine-related haemolysis among glucose-6-phosphate deshydrogenase deficient patients. At the end of the century, it progressively evolved into Pharmacogenomics, investigating simultaneously multiple gene targets till covering the whole genome in relation with altered drug response.

8 Jan 2010

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the 725th event (patient death) has been reached in its pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy.

8 Jan 2010

Prolia drug expected to garner blockbuster sales in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the U.S. Food and Drug Administration's (FDA) recent request for postmarketing surveillance of Amgen's Prolia, the drug's expected launch this year in the United States and Europe for the treatment of osteoporosis will drive Prolia to garner blockbuster sales in 2018..

8 Jan 2010

Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study

ACCESS PHARMACEUTICALS, INC., today announced that it has completed enrollment and evaluation of the last additional cohort of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two prior platinum based treatment regimens.

8 Jan 2010

Business leaders should continue to monitor H1N1 risk management to alleviate major impact on costs and revenues

The swine flu pandemic may be off the media’s radar screen, but business executives can ill afford to rest easy. Experts from the National Center for Critical Incident Analysis (NCCIA), who have studied how to respond to pandemics and bioterrorism attacks, warn that executives need to continue to monitor and manage unknown risk factors that might cause the flu to have a major impact upon costs and revenues.

8 Jan 2010

Amira Pharmaceuticals achieves another development milestone in its FLAP program

Amira Pharmaceuticals, Inc. announced today that it has achieved another development milestone in its FLAP program, which is partnered with GlaxoSmithKline. This milestone is related to the successful development of a solid dose formulation, which is critical for future development and commercialization activities.

8 Jan 2010

Ligand Pharmaceuticals receives $1 million as payment from N. V. Organon

Ligand Pharmaceuticals Incorporated announced today that it has received a $1 million milestone payment from N. V. Organon, a subsidiary of Merck & Co., Inc., stemming from its research collaboration that expired on December 31, 2009.

8 Jan 2010

3Sbio submits registrational clinical trial application for Feraheme injection

3SBio Inc., a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has submitted its application for a registrational clinical trial to the Chinese State Food and Drug Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous use.

8 Jan 2010

Teva Pharmaceutical Industries presents updated strategy to deliver profitable growth by 2015

During its investor meeting today, Teva Pharmaceutical Industries Ltd. presented an updated strategy, highlighting key opportunities for growth and announcing its long-term goals of reaching revenues of $31 billion and non-GAAP net income of $6.8 billion, or 22% of revenues, by 2015.

8 Jan 2010

Pharmaceutical companies working on nearly 100 life-changing medicines for HIV/AIDS

Medical News Today recently reported that America's pharmaceutical research and biotechnology companies are working on nearly 100 life-changing medicines for diseases affecting people with HIV/AIDS, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).

8 Jan 2010

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company specializing in the development and GMP manufacture of monoclonal antibodies, fusion proteins and other therapeutic protein products, and Iconic Therapeutics, a company focused on the development of treatments for wet adult macular degeneration (wet AMD) and other ophthalmic diseases, today announced the completion of the manufacture of the first GMP lot of hI-con1(TM) recombinant Fc-Factor VII fusion protein.

8 Jan 2010

Hi-Tech Pharmacal receives clearance from FDA to market Tropazone lotion

Hi-Tech Pharmacal Co., Inc. announced today that it received clearance from the FDA to market Tropazone™ lotion, a prescription dermatological product which will be promoted by Hi-Tech’s branded marketing subsidiary, ECR Pharmaceuticals Co., Inc. The product is indicated for the treatment of various dermatological conditions including atopic dermatitis, allergic contact dermatitis, and radiation dermatitis.

8 Jan 2010

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Elixir Pharmaceuticals, Inc. announced today that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington’s Disease.

8 Jan 2010

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

Reata Pharmaceuticals, Inc. (Reata) and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) announced today that they have entered into a licensing agreement that provides Kyowa Hakko Kirin with the exclusive rights to develop and commercialize Reata’s lead compound, bardoxolone methyl (bardoxolone), in Japan and other selected Asian markets.

8 Jan 2010

China Medicine enters into Stock Subscription Agreement with OEP

China Medicine Corporation ("China Medicine" or "the Company"), primarily a leading distributor and a developer of Western pharmaceuticals, traditional Chinese medicines ("TCM"), and other nutriceuticals today announced that it has entered into a Stock Subscription Agreement for an equity private placement (the "Subscription Agreement") with One Equity Partners ("OEP"), the global private equity investment arm of JPMorgan Chase & Co.

7 Jan 2010

Particle Sciences to acquire HORIBA's Raman/Particle Characterization System

Particle Sciences Inc., a leading pharmaceutical CRO, is adding to its formulation and characterization abilities through a cooperative agreement with HORIBA Scientific. Under the agreement Particle Sciences will acquire a HORIBA Raman/Particle Characterization System.

7 Jan 2010

Prometheus Laboratories executes $260 million senior secured credit facility

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced that it has executed a $260 million senior secured credit facility. The credit facility consists of a $210 million term loan and a $50 million revolving credit line.

7 Jan 2010

FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet(TM)) for first-line therapy of HER2 positive metastatic breast cancer.

7 Jan 2010

Sales figures for Abstral presented in a press release in Europe

Orexo AB announces today that its partner ProStrakan Group plc has presented its sales figures for Abstral in Europe in a press release. ProStrakan states that sales of Abstral underwent a strong development in 2009 and sales in the range of GBP 5 M – GBP 6 M were achieved for full-year.

7 Jan 2010

Pharmaceuticals News and Research

Three new retail stores of China Yongxin Pharmaceuticals opened in 2009

ESF-UB Conference to concentrate on potentially clinically relevant polymorphisms

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Prolia drug expected to garner blockbuster sales in 2018

Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study

Business leaders should continue to monitor H1N1 risk management to alleviate major impact on costs and revenues

Amira Pharmaceuticals achieves another development milestone in its FLAP program

Ligand Pharmaceuticals receives $1 million as payment from N. V. Organon

3Sbio submits registrational clinical trial application for Feraheme injection

Teva Pharmaceutical Industries presents updated strategy to deliver profitable growth by 2015

Pharmaceutical companies working on nearly 100 life-changing medicines for HIV/AIDS

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Hi-Tech Pharmacal receives clearance from FDA to market Tropazone lotion

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

China Medicine enters into Stock Subscription Agreement with OEP

Particle Sciences to acquire HORIBA's Raman/Particle Characterization System

Prometheus Laboratories executes $260 million senior secured credit facility

FDA issues Fast Track Designation to Sopherion Therapeutics' Myocet

Sales figures for Abstral presented in a press release in Europe

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence